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Elevated Preoperative C-reactive Protein Predicts Poor
Cancer Specific Survival in Patients Undergoing Resection
for Non-small Cell Lung Cancer
Caroline O’Dowd, MBChB, MRCP,* Laura A. McRae, MBChB,*† Donald C. McMillan,†
Alan Kirk, MBChB, FRCS,‡ and Robert Milroy, MBChB, FRCP, MD*
Background: Although only the minority of patients with non-small
cell lung cancer (NSCLC) are suitable for surgical resection, it offers
the best possibility of cure. The aim of this study was to examine the
relationship between the clinicopathological status, the preoperative
systemic inflammatory response, and survival in patients undergoing
potentially curative resection for NSCLC.
Methods: Data from 96 patients who underwent resection of
NSCLC between 2000 and 2003 were collected retrospectively and
that for 2004–2006 prospectively.
Results: All patients had Eastern cooperative oncology group per-
formance status 0 or 1. No patient had T4, unresectable nodal or
metastatic disease, and all macroscopic tumors were removed, with
subsequent negative surgical margins. The majority of patients were
older than 60 years (71%), men (57%), underwent a lobectomy
(65%), and had tumor, node, metastasis stage I disease (66%). Of the
markers of the systemic inflammatory response, white cell count,
C-reactive protein, and albumin, only an elevated C-reactive protein
(10 mg/L) was associated with cancer-specific survival. On mul-
tivariate analysis, only tumor, node, metastasis stage (hazard ratio
1.88, 95% confidence interval 1.34–2.63, p  0.001) and preop-
erative C-reactive protein (hazard ratio 1.67, 95% confidence
interval 1.01–2.83, p  0.05) retained independent significance.
Those patients with a preoperative C-reactive protein concentra-
tion 10 mg/L had a median survival of 26.2 months compared
with 75.9 months in those patients with a C-reactive protein 10
mg/L (p  0.05).
Conclusion: The results of this study indicate that the presence of a
systemic inflammatory response predicts poor outcome in patients
who have undergone potentially curative resection for lung cancer.
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C-reactive protein, White cell count, Albumin, Survival.
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Non-small cell lung cancer (NSCLC) is the most commoncause of cancer-related death in North America and
Western Europe. Most patients present with advanced inop-
erable disease and the majority die within 12 months.1 Al-
though only suitable in the minority of patients, approxi-
mately 11% in the UK,2 surgery confers the greatest chance
of long-term cure.
Despite careful selection, in terms of tumor, node,
metastasis (TNM) stage and fitness, approximately 30% of
patients with early-stage disease, who undergo surgical re-
section, will develop metastatic spread and die of their dis-
ease.3 Therefore, there has been a longstanding interest in
identifying those patients with apparently early-stage disease
most likely to die of lung cancer. Ideally, a factor or combi-
nation of factors would clearly stratify patients who will
remain disease free and are “cured” from those who will
ultimately die of their cancer.4 Currently, TNM stage is the
most widely used tool to predict the likely outcome. How-
ever, despite revisions, there is considerable “overlap” in
survival between the stages.3,5,6
The systemic inflammatory response, as manifest by
alterations in white cell count and circulating concentrations
of the acute-phase proteins, C-reactive protein, and albumin,
has been shown to be an independent prognostic factor in
various advanced cancers7–9 including non-small cell lung
cancer.10–13
More recently, it has been reported that when various
tumors were resected with curative intent, an elevated C-
reactive protein concentration has been shown to be associ-
ated with poorer cancer-specific survival, independent of
pathologic stage.14–17
Therefore, it is of interest that Hara et al.18 recently
reported that, in 203 patients who had undergone potentially
curative resection for NSCLC, an elevated preoperative C-
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reactive protein concentration was associated with poorer
cancer-specific survival independent of TNM stage. In addi-
tion, it has been reported that an elevated preoperative C-re-
active protein concentration was associated with a poorer
complete resection rate,19 larger tumors size, and lymphovas-
cular invasion.20 However, the prognostic value of C-reactive
protein has not been shown in other studies.21,22
The aim of this study was to examine the relationship
between clinicopathologic status, systemic inflammatory re-
sponse (measured before surgery), and cancer-specific sur-
vival in patients undergoing potentially curative resection of
NSCLC.
PATIENTS AND METHODS
Patients
Patients with histologically proven NSCLC who, on the
basis of surgical findings and/or preoperative chest and ab-
dominal computed tomography, were considered to have
undergone a potentially curative resection and had routine
laboratory measurement of albumin and C-reactive protein in
the 2 months before surgery, between March 2000 and
November 2006 in a single unit in the North Glasgow NHS
Trust, were included in the study. Patients who died within 30
days of surgery were excluded from the analysis. During this
period, data were collected for 96 of 108 patients who
underwent resection for non-small cell lung cancer. Data for
2000–2003 were collected retrospectively and that for 2004–
2006 prospectively.
All patients had Eastern cooperative oncology group
performance status 0 or 1. No patient had T4, unresectable
nodal or metastatic disease, and all macroscopic tumor was
removed, with subsequent negative surgical margins. All
patients underwent thoracotomy, and no patient underwent
video-assisted thoracoscopic surgery. Patients were staged
according to the 1997 TNM classification of lung tumors.5 No
patient had computed tomography-positron emission tomog-
raphy scanning because this study predated routine computed
tomography-positron emission tomography scanning in the
staging of radically treatable patients with lung cancer. Pre-
operative white cell count was available in 73 patients.
After surgery, patients were considered to have under-
gone adjuvant treatment if they received chemotherapy
(mainly cisplatin based) and/or radical radiotherapy.
The Research Ethics Committee of North Glasgow
NHS Trust approved the study.
Methods
Serum concentrations of albumin and C-reactive pro-
tein were measured by a bromcresol green dye-binding
method and turbidometric assay, respectively, using an auto-
analyzer (Abbott Diagnostics, Abbott Park, IL). The limit of
detection for C-reactive protein was 6 mg/L. The inter- and
intra-assay variability of white cell count, albumin, and C-
reactive protein were less than 10% as assessed by routine
quality control procedures. A C-reactive protein concentra-
tion of 10 mg/L was considered to indicate the presence of
a systemic inflammatory response.7,8
Statistics
Grouping of the variables age, tumor type, operation,
white cell count, and albumin was carried out using standard
thresholds.9,11,22 C-reactive protein concentrations were also
grouped (10/10 mg/L) as previously described.7 Values
from groups of patients were compared using contingency
table analysis (2) as appropriate. Survival was analyzed
using the Cox proportional hazards model; deaths up to the
end of January 2009 were included in the analysis. For
multivariate survival analysis, a stepwise backward proce-
dure to derive a final model of the variables that had a
significant independent relationship with survival was used.
To remove a variable from the model, the corresponding p
value had to be 0.10. Analysis was performed using SPSS
software (SPSS Inc., Chicago, IL).
RESULTS
The clinicopathological characteristics of patients with
operable NSCLC at diagnosis are shown in Table 1. The
TABLE 1. Clinicopathological Characteristics and Cancer-Specific Survival of Patients Undergoing Potentially Curative
Resection for NSCLC
Patients
n  96
Univariate Survival Analysis Multivariate Survival Analysis
Hazard Ratio
(95%CI) p
Hazard Ratio
(95%CI) p
Age (60/60 yr) 26/70 1.08 (0.59–1.97) 0.807
Sex (female/male) 40/56 1.45 (0.85–2.47) 0.170
Type (adeno/squamous/other) 47/39/10 1.21 (0.84–1.74) 0.310
Operation (lobectomy/pneumonectomy/wedge
resection)
64/23/9 1.42 (1.00–2.02) 0.048 0.102
TNM stage (I/II/III) 65/19/12 1.94 (1.39–2.70) 0.001 1.88 (1.34–2.63) 0.001
White cell count (8.5/8.5–11.0/11  109/L) 43/16/14 0.84 (0.56–1.24) 0.375
Albumin (35/35 g/L) 90/6 0.85 (0.26–2.71) 0.780
C-reactive protein (10/10 mg/L) 49/47 1.73 (1.02–2.98) 0.041 1.67 (1.01–2.83) 0.047
Adjuvant treatment (yes/no) 12/84 0.56 (0.22–1.40) 0.215
TNM, tumor, node, metastasis.
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majority of patients were older than 60 years (73%), men (58%),
underwent a lobectomy (67%), and had TNM stage I disease
(68%). Nineteen percent patients had an elevated white cell
count, 7% patients had a low albumin concentration, and 48%
patients had an elevated C-reactive protein concentration. Thir-
teen percent of patients received adjuvant treatment.
The minimal follow-up period was 28 months; the
median follow-up period of the survivors was 75 months. In
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FIGURE 1. The relationship between tumor, node, metastasis stage (I, II, and III from top to bottom) and cancer-specific sur-
vival in patients with non-small cell lung cancer.
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FIGURE 2. The relationship between preoperative C-reactive protein (10 mg/L/10 mg/L from top to bottom) and cancer-
specific survival in patients with non-small cell lung cancer.
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the follow-up period, 58 patients died of their disease. On
univariate analysis, operation (p  0.10), TNM stage (p 
0.01, Figure 1), and preoperative C-reactive protein concen-
trations (p  0.05, Figure 2) were significantly associated
with cancer-specific survival (Table 1). On multivariate anal-
ysis of these significant variables, only TNM stage (hazard
ratio 1.88, 95% confidence interval 1.34–2.63, p  0.01) and
preoperative C-reactive protein (hazard ratio 1.67, 95% con-
fidence interval 1.01–2.83, p  0.05) retained independent
significance.
The relationship between the presence of an elevated
preoperative C-reactive protein concentration and clinico-
pathological characteristics are shown in Table 2. There were
no significant associations with the clinicopathological char-
acteristics with the exception of albumin, which was lower in
the elevated C-reactive protein group (p  0.01). The patient
group with a normal preoperative C-reactive protein concen-
tration (10 mg/L) had a median survival of 75.9 months
compared with 26.2 months in the elevated C-reactive protein
group (p  0.05, Table 2).
DISCUSSION
Surgical resection remains the best prospect for long-
term survival in patients with NSCLC. Currently, in patients
undergoing surgery, prognostic factors are mainly based on
the pathologic findings from the resected tumor. However,
this means that the assessment of prognosis occurs after a
major operation with significant morbidity and mortality.
Therefore, it is of considerable interest that in this study, an
elevated circulating concentration of C-reactive protein (10
mg/L) was associated with poor survival independent of
TNM stage. Those patients with a normal preoperative C-
reactive protein concentration (10 mg/L) had a median
survival of 72.5 months compared with 26.2 months in those
patients with an elevated C-reactive protein concentration.
Dichotomised variables were used in the analysis based
on previous work on the value of systemic inflammatory
response markers in predicting survival in operable cancer.23
The value of standardized threshold (10/10 mg/L) for
C-reactive protein is that it can have routine clinical utility.
Although continuous variables may have a more close asso-
ciation with outcome, they are rarely useful in clinical deci-
sion making.
It has been previously shown that, in patients with
primary operable gastrointestinal cancers, approximately
one-third to one-half of patients had an elevated circulating
concentration of C-reactive protein preoperatively and that
these patients had a significantly poorer outcome independent
of tumor stage.14–17 It may be that because C-reactive protein
concentration is independent of tumor stage, it might form the
basis of a new prognostic score that reflects not only the
tumor anatomy but also the host response. Indeed, this ap-
proach has recently been used to improve the prediction of
outcome in patients who underwent potentially curative re-
section for esophageal and colorectal cancer.24,25
Acute-phase proteins are just one aspect of the systemic
inflammatory response.26 There are cellular components of
the systemic inflammatory response and an elevated white
cell count has been reported to have prognostic value in
patients with a variety of common solid tumors.9,27,28 How-
ever, in this study, elevated white cell count seemed to have
no prognostic value in patients with primary operable
NSCLC.
The results of this study may also offer insight into the
nature of the relationship between the systemic inflammatory
response and survival in patients with primary operable
NSCLC. C-reactive protein may play a pivotal role in the
tumor-host relationship because it is recognized to be not
only an activator of innate immunity but also a modulator of
adaptive immunity.29 Moreover, the increase of C-reactive
protein seems to be a precursor to tumor dissemination and
progressive involuntary loss of weight and lean tissue,30,31
which are key factors in determining cancer survival.
In this study, there were a number of limitations. The
degree of comorbid disease and the smoking history of the
patients were not accurately recorded. Recently, Koch et al.32
reported that the combination of smoking and an elevated
C-reactive protein independently predicted poor survival in
patients with advanced-stage lung cancer. However, no pa-
tients had comorbid disease significant enough to preclude
surgery, and all patients were advised to stop smoking before
surgery. Therefore, it is unclear whether smoking would have
independently predicted survival in this study. This study did
not examine the relationship between tumor pathologic fea-
ture other than tumor type and TNM stage. However, Jones et
al.33 reported that fibrinogen and C-reactive protein concen-
trations were directly associated with tumor size in patients
undergoing resection of non-small cell lung cancer.
This relatively small study requires verification in
larger prospective cohorts, particularly within the context
of randomized controlled trials. However, if an elevated C-
reactive protein concentration is confirmed to predict a poorer
outcome, it may be the case that patients with resected
TABLE 2. The Relationship Between Preoperative C-reactive
Protein (10/10 mg/L) and Clinicopathological
Characteristics and Cancer-Specific Survival of Patients
Undergoing Potentially Curative Resection for NSCLC
C-reactive
Protein
(<10 mg/L,
n  49)
C-reactive
Protein
(>10 mg/L,
n  47) p
Age (60/60 yr) 13/36 13/34 0.901
Sex (female/male) 20/29 20/27 0.864
Type (adeno/squamous/other) 28/16/5 19/23/5 0.210
Operation (lobectomy/
pneumonectomy/wedge
resection)
34/8/7 30/15/2 0.740
TNM stage (I/II/III) 37/7/5 28/12/7 0.154
White cell count (8.5/
8.5–11.0/11  109/L)
25/5/6 18/11/8 0.166
Albumin (35/35 g/L) 49/0 41/6 0.010
Adjuvant treatment (yes/no) 45/4 39/8 0.192
Survival (mo)a 75.9 (37.7–114.1) 26.2 (5.8–46.7) 0.038
a Median (95% confidence interval).
TNM, tumor, node, metastasis.
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NSCLC, yet a high inflammatory profile preoperatively, un-
dergo more intensive follow-up and/or adjuvant treatment.
Alternatively, it would be important to consider whether
modulation of the systemic inflammatory response may be a
useful approach in these patients in the perioperative period.
In summary, the results of this study indicate that, in
patients who have undergone potentially curative resection
for NSCLC, the presence of an elevated C-reactive protein
predicts poor outcome.
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